# Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

> **NCT03124459** · PHASE2 · TERMINATED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 63 (actual)

## Conditions studied

- Charcot-Marie-Tooth Disease

## Interventions

- **DRUG:** ACE-083
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03124459
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-31
- **Primary completion:** 2020-03-11
- **Final completion:** 2020-03-11
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** (Investigation of ACE-083 for use in patients with CMT is being discontinued as it did not achieve functional secondary endpoints in the A083-03 trial.
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03124459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03124459, "Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03124459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*